Show simple item record

dc.contributor.authorJamal, Tameemen_US
dc.date.accessioned2018-02-06T20:20:37Z
dc.date.available2018-02-06T20:20:37Z
dc.date.issued2017
dc.identifier.urihttps://hdl.handle.net/2144/26755
dc.description.abstractTechnologies for early detection of tumors is critical for better therapy outcome and overall change in cancer survival. These assays must be capable of detecting tumors at early stages in order to prevent metastasis of the tumor and help reduce mortality. Biological molecules can serve as markers that can indicate the presence of cancerous cells. Current biomarkers approved by the FDA include CA 125, which is a tumor associated antigen (TAA). However, the sensitivities of these TAAs is not high enough to detect at early stages of disease. Recent technologies have found that antibodies that recognize these TAAs, also known as autoantibodies, provide more sensitive means to screen for tumors. This review aims to present recent literature data relative to the field of cancer diagnosis and treatment. However, one should note that this article covers only fraction of the broad science behind this subject.en_US
dc.language.isoen_US
dc.subjectOncologyen_US
dc.subjectAutoantibodiesen_US
dc.subjectBiomarkersen_US
dc.subjectCanceren_US
dc.subjectImmunologyen_US
dc.subjectEarly detectionen_US
dc.subjectTumor associated antigenen_US
dc.titleCancer biomarkers, and novel techniques for detectionen_US
dc.typeThesis/Dissertationen_US
dc.date.updated2017-11-02T01:12:45Z
etd.degree.nameMaster of Scienceen_US
etd.degree.levelmastersen_US
etd.degree.disciplineMedical Sciencesen_US
etd.degree.grantorBoston Universityen_US


This item appears in the following Collection(s)

Show simple item record